In Belgium pharmaceutical companies can in some instances agree with the authorities on price-volume contracts where "normal" reimbursement is unlikely. A price-volume contract aims at controlling the budget of expensive medicinal products, even at increasing volumes.
Our team has compiled a document summarizing the most recent views of the Belgian authorities concerning these price-volume contracts.
Carefull analysis of these data leads to the conclusion that applicants facing a refusal for their innovative medicinal product can under certain conditions benefit from a 3 to 6-year reimbursement.
Do not hesitate to contact us if you wish to know more about the possibilities for your product.